
|Articles|September 1, 2004
Alefacept's safety profile encouraging
New York - Recent data suggests that refinements in dosing techniques can improve clinical outcomes with alefacept (Amevive, Biogen).
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Nearly Half of Female Psoriasis Patients Report IPV, Study Finds
3
New Analysis Finds Radiofrequency Microneedling Superior for Rosacea Erythema and Patient Satisfaction
4
Experts See Promise in AI for Atopic Dermatitis Care
5


















